David O'Malley, MD
The entrance of PARP inhibitors into the treatment landscape of ovarian cancer has provided the opportunity to treat patients in the frontline and recurrent settings more effectively, and has also resulted in more durable outcomes, according to David O’Malley, MD.
, O’Malley, a professor in the Department of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center, shared his insight on the findings from the SOLO-1 and QUADRA studies, as well as the future of PARP inhibition in ovarian cancer.
OncLive: Could you reflect on the impact of the SOLO-1 findings?
This will lead us to revisit our treatment of women with ovarian cancer in multiple ways. One of which is early germline testing for patients with mutations in BRCA1/2,
and then in those patients, utilizing the combination of cytotoxic chemotherapy followed by PARP. The improvements that we saw in PFS and the 3-year disease-free survival were marked, and even better than we had anticipated. Ultimately, our goal of curing more patients may now be achievable in patients with BRCA1/2
What are the findings from the QUADRA analysis?
This gives us further support that PARP inhibitors may be utilized in patients who have had received prior chemotherapy as a treatment option. However, as we have seen with the recent SOLO-1 data, our best option for patients is upfront or first-line therapy with PARP inhibitors. Additionally, with data from 3 randomized prospective trials, if patients with BRCA
-positive disease have not had the opportunity to have PARP inhibitors upfront, they should be utilized in platinum-sensitive maintenance therapy.
... to read the full story